Fatostatin (hydrobromide) – 25 mg

Brand:
Cayman
CAS:
298197-04-3
Storage:
-20
UN-No:
Non-Hazardous - /

Sterol regulatory element binding proteins (SREBPs) are transcription factors that have pivotal roles in lipogenesis and fat metabolism.{15316} The activation of SREBPs requires escort to the Golgi by SREBP cleavage-activating protein (SCAP) followed by proteolytic release of SREBP from the Golgi.{15551} Fatostatin is an inhibitor of SREBP activation, preventing SCAP-mediated escort of either SREBP-1 or SREBP-2 to the Golgi (IC50 = 5.6 µM).{17397,23867} This blocks constitutive SREBP-mediated gene expression in the human prostate cancer cell line DU145.{17397} Fatostatin prevents insulin-induced adipogenesis of 3T3-L1 cells as well as growth induced by insulin-like growth factor 1 in DU145 cells (IC50 = 0.1 µM).{23869} Through its actions on SCAP/SREBP-1, it inhibits high glucose-induced upregulation of TGF-β in primary rat mesangial cells.{23868} This compound also alters lipid metabolism in vivo, reducing hepatic fat accumulation in ob/ob mice.{17397}  

 

SKU: - Category:

Description

An inhibitor of SREBP activation, preventing SCAP-mediated escort of either SREBP-1 or SREBP-2 to the Golgi (IC50 = 5.6 µM); blocks SREBP-mediated gene expression; inhibits high glucose-induced upregulation of TGF-β in primary rat mesangial cells; reduces hepatic fat accumulation in ob/ob mice


Formal name: 4-[4-(4-methylphenyl)-2-thiazolyl]-2-propyl-pyridine, hydrobromide

Synonyms:  125B11

Molecular weight: 375.3

CAS: 298197-04-3

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Cancer|Transcription Factors||Research Area|Cell Biology|Cell Signaling|Growth Factor Receptors||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity||Research Area|Endocrinology & Metabolism|Nutrient Sensing